Peptide
Knowledgebase

Synthetic 15-amino acid fragment from human gastric juice. Studied in musculoskeletal injury models, angiogenesis (VEGFR2 pathway), and gastrointestinal cytoprotection assays across 36+ preclinical publications. In vitro research compound only.

Synthetic heptapeptide corresponding to the actin-binding domain of Thymosin Beta-4. Studied for wound healing via G-actin sequestration, cell migration, angiogenesis, and cardiac progenitor cell activation.

Naturally occurring tripeptide-copper complex isolated from human plasma in 1973. Over four decades of published preclinical data on ECM gene expression, antioxidant enzyme pathways, and fibroblast assay models. Studied in wound healing and extracellular matrix research.

First 29 residues of endogenous GHRH. Previously FDA-approved for paediatric use. Preserves hypothalamic-pituitary negative feedback and stimulates pituitary GH mRNA transcription — key research distinction from exogenous recombinant GH.

Among the most potent GH secretagogues characterised on a per-mole basis. Unique for dual receptor binding at GHS-R1a in the pituitary and CD36 in cardiac tissue — enabling concurrent GH and cardiovascular research applications.

16-amino acid peptide encoded by the mitochondrial genome. Discovered 2015. Declines with age, induced by exercise in published human studies. Activates AMPK, promotes GLUT4-mediated glucose uptake in preclinical models. Differences in physical capacity measures reported in late-life dosing studies in mice.

Synthetic tetrapeptide from the pineal gland extract epithalamin. Studied for proposed telomerase activation in somatic cells, epigenetic modulation during neurogenesis, and melatonin-related circadian regulation in aged animal models.

Registered drug in Russia and Ukraine for stroke management. Upregulates BDNF, modulates immune and vascular gene expression in ischaemic brain tissue. resting-state fMRI in 52 healthy humans showed distinct amygdala-temporal connectivity changes.

Registered drug in Russia since 2009 for GAD and neurasthenia. Allosterically modulates GABA-A receptor affinity for endogenous GABA in preclinical models. Anxiolytic pathway activity observed without classical benzodiazepine co-effects in rodent studies. 25-gene overlap with direct GABA transcriptomic effects.